SlideShare a Scribd company logo
Stock Analysis of Medical Devices Abiomed Inc. (ABMD) 		Thoratec Corp. (THOR)  Impella - World’s  smallest pump for left ventricle Heartmate II LVAD DePaul University FIN 524 Wanda Hartmann Oehrli
Outline ABMD and THOR company’s values Abiomed Inc. (ABMD) Recovering Hearts. Saving LivesThoratec Corp. (THOR) Life Restored Description & competitive environment Valuation of Medical Instruments & Supplies Industry More attractively valued company
AbiomedThoratec ,[object Object]
Impella – world’s smallest heart pump
Protect, support, assist in recovery after surgery or heart attack
 High risk patient
 minimally invasive  - angioplasty Future ,[object Object],Advanced Stage Heart Failure  –ventricular assist Heartmate II Heartmate III http://www.marketwatch.com/video/asset/help-for-damaged-hearts/24626C3F-2C52-4AEF-809C-F922AE7A8960 http://www.thoratec.com/videos/about-thoratec.aspx
Medical Devices Competitive Environment Estimated worldwide sales > $300 B (2011) U.S. -largest market - estimated sales of roughly $95B (2010) Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT Aging population & lifestyle diseases (heart disease, obesity) Healthcare reform/ FDA policy & regulations Ave Financial Info Profit Margin 20% EV/Sales Multiple 3.5x EBITDA Multiple 12.8 Zacks Investment Report http://finance.yahoo.com/news/Medical-Devices-Industry-zacks-1123678571.html?x=0&.v=1  http://www.fool.com/investing/general/2011/02/25/the-magic-formula-for-these-medical-device-stocks.aspx http://www.nytimes.com/2009/11/05/business/05device.html http://www.horizonviewpartners.com/index.php?p=1_8_Medical-Device-Market
Comparison ABMD stock is up 68% yet EBITDA, Operating Margin and Net Income are Negative? Renewed optimism around sales of Abiomed'sImpella heart pump has been a key factor  behind the market run-up. Read more: CEO of red-hot Abiomed sells $1.1M in stock | Boston Business Journal
New generation of heart pumps Stock up 68% since start of year Great December Quarter 2010 More Patient increase 77% 7th consecutive quarter of triple digit reorder revenue Non-GAAP profitable quarter – first time in a long time Generated $5 M  $60M in Cash No debt Abiomed
ABMD Income Statement Revenue growth 22% ave increasing less negative less negative EBITA = Rev – COGS - SG&A + D&A= EBITDA : neg
ABMD Income Statement
ABMD Balance Sheet Current Ratio =  4.58 No Debt
ABMD Balance Sheet Long Term Debt to Equity = 0 Debt to Equity  =  0 Total Debt  = 0 License Leverage = TA =129570  = 1.2     TE  107956 Quick(Acid Test) = 3.74 =  4788 + 53477+13516                18,064 Cash = 3.23 = 4788 + 53477         18,064 ROE = NI/SE=  N/A P/E = Price /earnings = N/A EPS = N/A EBITDA MULT= __EV___= N/A                              EBITDA Sales Mult = 646.54M/95.60M = 6.76
ABMD Cash Flow less negative increasing increasing
ABMD Cash Flow increasing decreasing increasing
THOR  Income Statement Revenue Growth 39% increasing increasing increasing EBITA = Rev – COGS - SG&A + D&A= EBITDA :126.44M
THOR  Balance Sheet increasing Current Ratio =  3.16 increasing same

More Related Content

Similar to Stock Analysis Medical Devices

Graduation Presentation
Graduation PresentationGraduation Presentation
Graduation Presentation
aburakan69
 
Graduation Presentation
Graduation PresentationGraduation Presentation
Graduation Presentation
aburakan69
 
Ppt ch05 perfect competition 33
Ppt ch05 perfect competition 33Ppt ch05 perfect competition 33
Ppt ch05 perfect competition 33
noorsingh15
 
firm cost revenue and objectives
firm cost revenue and objectivesfirm cost revenue and objectives
firm cost revenue and objectives
YousafDar1
 
ADM 658: Chapter 3 - Financial Analysis (Ratio)
ADM 658: Chapter 3 - Financial Analysis (Ratio)ADM 658: Chapter 3 - Financial Analysis (Ratio)
ADM 658: Chapter 3 - Financial Analysis (Ratio)
FSPPP - UiTM ( AM225 )
 
Med Hub (2016)
Med Hub (2016)Med Hub (2016)
Med Hub (2016)
Khandakar Shameel Murtaz
 
objectives of a firm
objectives of a firmobjectives of a firm
objectives of a firm
Vibha Jain
 
Managerial Economics Session 7
Managerial Economics Session 7Managerial Economics Session 7
Managerial Economics Session 7
Rachit Kapoor
 
Pfie 6262013
Pfie 6262013Pfie 6262013
TKEQ Final Presentation
TKEQ Final PresentationTKEQ Final Presentation
TKEQ Final Presentation
Mohamed Dassouki
 
Bp training chag session 3
Bp training chag session 3Bp training chag session 3
Bp training chag session 3
Sajjad Hamid
 
Chap4
Chap4Chap4
Chap4
Shu Shin
 
Chap4
Chap4Chap4
Chap4
Shu Shin
 
The Finance Perspective: The Business Model for the Subscription Economy
The Finance Perspective: The Business Model for the Subscription EconomyThe Finance Perspective: The Business Model for the Subscription Economy
The Finance Perspective: The Business Model for the Subscription Economy
Zuora, Inc.
 
Advanced strategic management @ bec doms
Advanced strategic management @ bec domsAdvanced strategic management @ bec doms
Advanced strategic management @ bec doms
Babasab Patil
 
Fsa.pp
Fsa.ppFsa.pp
Fsa.pp
Ameenababs
 
Working with Financial StatementsCh. 3.docx
Working with Financial StatementsCh. 3.docxWorking with Financial StatementsCh. 3.docx
Working with Financial StatementsCh. 3.docx
dunnramage
 
CITIZEN Kenya Market Presentation
CITIZEN Kenya Market PresentationCITIZEN Kenya Market Presentation
CITIZEN Kenya Market Presentation
Laila C. Erut Morinigo - Island Gate LLC
 
Profit maximisation & its alternatives
Profit maximisation & its alternativesProfit maximisation & its alternatives
Profit maximisation & its alternatives
Awesh Bhornya
 
Revision Webinar - Business Profits
Revision Webinar - Business ProfitsRevision Webinar - Business Profits
Revision Webinar - Business Profits
tutor2u
 

Similar to Stock Analysis Medical Devices (20)

Graduation Presentation
Graduation PresentationGraduation Presentation
Graduation Presentation
 
Graduation Presentation
Graduation PresentationGraduation Presentation
Graduation Presentation
 
Ppt ch05 perfect competition 33
Ppt ch05 perfect competition 33Ppt ch05 perfect competition 33
Ppt ch05 perfect competition 33
 
firm cost revenue and objectives
firm cost revenue and objectivesfirm cost revenue and objectives
firm cost revenue and objectives
 
ADM 658: Chapter 3 - Financial Analysis (Ratio)
ADM 658: Chapter 3 - Financial Analysis (Ratio)ADM 658: Chapter 3 - Financial Analysis (Ratio)
ADM 658: Chapter 3 - Financial Analysis (Ratio)
 
Med Hub (2016)
Med Hub (2016)Med Hub (2016)
Med Hub (2016)
 
objectives of a firm
objectives of a firmobjectives of a firm
objectives of a firm
 
Managerial Economics Session 7
Managerial Economics Session 7Managerial Economics Session 7
Managerial Economics Session 7
 
Pfie 6262013
Pfie 6262013Pfie 6262013
Pfie 6262013
 
TKEQ Final Presentation
TKEQ Final PresentationTKEQ Final Presentation
TKEQ Final Presentation
 
Bp training chag session 3
Bp training chag session 3Bp training chag session 3
Bp training chag session 3
 
Chap4
Chap4Chap4
Chap4
 
Chap4
Chap4Chap4
Chap4
 
The Finance Perspective: The Business Model for the Subscription Economy
The Finance Perspective: The Business Model for the Subscription EconomyThe Finance Perspective: The Business Model for the Subscription Economy
The Finance Perspective: The Business Model for the Subscription Economy
 
Advanced strategic management @ bec doms
Advanced strategic management @ bec domsAdvanced strategic management @ bec doms
Advanced strategic management @ bec doms
 
Fsa.pp
Fsa.ppFsa.pp
Fsa.pp
 
Working with Financial StatementsCh. 3.docx
Working with Financial StatementsCh. 3.docxWorking with Financial StatementsCh. 3.docx
Working with Financial StatementsCh. 3.docx
 
CITIZEN Kenya Market Presentation
CITIZEN Kenya Market PresentationCITIZEN Kenya Market Presentation
CITIZEN Kenya Market Presentation
 
Profit maximisation & its alternatives
Profit maximisation & its alternativesProfit maximisation & its alternatives
Profit maximisation & its alternatives
 
Revision Webinar - Business Profits
Revision Webinar - Business ProfitsRevision Webinar - Business Profits
Revision Webinar - Business Profits
 

Stock Analysis Medical Devices

  • 1. Stock Analysis of Medical Devices Abiomed Inc. (ABMD) Thoratec Corp. (THOR) Impella - World’s smallest pump for left ventricle Heartmate II LVAD DePaul University FIN 524 Wanda Hartmann Oehrli
  • 2. Outline ABMD and THOR company’s values Abiomed Inc. (ABMD) Recovering Hearts. Saving LivesThoratec Corp. (THOR) Life Restored Description & competitive environment Valuation of Medical Instruments & Supplies Industry More attractively valued company
  • 3.
  • 4. Impella – world’s smallest heart pump
  • 5. Protect, support, assist in recovery after surgery or heart attack
  • 6. High risk patient
  • 7.
  • 8. Medical Devices Competitive Environment Estimated worldwide sales > $300 B (2011) U.S. -largest market - estimated sales of roughly $95B (2010) Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT Aging population & lifestyle diseases (heart disease, obesity) Healthcare reform/ FDA policy & regulations Ave Financial Info Profit Margin 20% EV/Sales Multiple 3.5x EBITDA Multiple 12.8 Zacks Investment Report http://finance.yahoo.com/news/Medical-Devices-Industry-zacks-1123678571.html?x=0&.v=1 http://www.fool.com/investing/general/2011/02/25/the-magic-formula-for-these-medical-device-stocks.aspx http://www.nytimes.com/2009/11/05/business/05device.html http://www.horizonviewpartners.com/index.php?p=1_8_Medical-Device-Market
  • 9. Comparison ABMD stock is up 68% yet EBITDA, Operating Margin and Net Income are Negative? Renewed optimism around sales of Abiomed'sImpella heart pump has been a key factor behind the market run-up. Read more: CEO of red-hot Abiomed sells $1.1M in stock | Boston Business Journal
  • 10. New generation of heart pumps Stock up 68% since start of year Great December Quarter 2010 More Patient increase 77% 7th consecutive quarter of triple digit reorder revenue Non-GAAP profitable quarter – first time in a long time Generated $5 M $60M in Cash No debt Abiomed
  • 11. ABMD Income Statement Revenue growth 22% ave increasing less negative less negative EBITA = Rev – COGS - SG&A + D&A= EBITDA : neg
  • 13. ABMD Balance Sheet Current Ratio = 4.58 No Debt
  • 14. ABMD Balance Sheet Long Term Debt to Equity = 0 Debt to Equity = 0 Total Debt = 0 License Leverage = TA =129570 = 1.2 TE 107956 Quick(Acid Test) = 3.74 = 4788 + 53477+13516 18,064 Cash = 3.23 = 4788 + 53477 18,064 ROE = NI/SE= N/A P/E = Price /earnings = N/A EPS = N/A EBITDA MULT= __EV___= N/A EBITDA Sales Mult = 646.54M/95.60M = 6.76
  • 15. ABMD Cash Flow less negative increasing increasing
  • 16. ABMD Cash Flow increasing decreasing increasing
  • 17. THOR Income Statement Revenue Growth 39% increasing increasing increasing EBITA = Rev – COGS - SG&A + D&A= EBITDA :126.44M
  • 18. THOR Balance Sheet increasing Current Ratio = 3.16 increasing same
  • 19. THOR Balance Sheet Long Term Debt to Equity = 0 Debt to Equity = TD = 138,165 = 0.22 TE 621360 Total Debt =TD= 138,165= 0.16 TA 837,743 License Leverage = TA = 837,743 = 1.35 TE 621,360 Quick(Acid Test) =2.80 = 524571 187017 Cash =2.40 = 448,143 187017 ROE = NI/SE= 58,166M/621,360 = 9% return P/E = Price/earnings = 35.18 EBITDA MULT= __EV___= 11.79 EBITDA Sales multiple = market cap/revenue = 1.80B/ 382.97M = 4.7
  • 20. THOR Cash Flows increasing increasing decreasing
  • 21. Conclusion: Which is More Valuable? http://biz.yahoo.com/p/s_ttmu.html